Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis
- 1 April 2007
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 71 (8), 771-777
- https://doi.org/10.1038/sj.ki.5002112
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Patterns of Pulmonary Complications Associated with SirolimusRespiration, 2006
- Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGFBlood, 2005
- Sirolimus for Kaposi's Sarcoma in Renal-Transplant RecipientsThe New England Journal of Medicine, 2005
- Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1Transplantation, 2005
- Vascular endothelial growth factor‐C gene therapy restores lymphatic flow across incision woundsThe FASEB Journal, 2004
- Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammationTrends in Immunology, 2004
- Sirolimus-Induced AngioedemaAmerican Journal of Transplantation, 2004
- Concurrent Induction of Lymphangiogenesis, Angiogenesis, and Macrophage Recruitment by Vascular Endothelial Growth Factor-C in MelanomaThe American Journal of Pathology, 2001
- Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesisOncogene, 2000
- Lymphatic Endothelial Tumors Induced by Intraperitoneal Injection of Incomplete Freund's AdjuvantExperimental Cell Research, 1999